Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias

Blood (2013) 122 (14): 2412–2424.

https://doi.org/10.1182/blood-2013-02-482125

Published: 2013

Includes: Supplemental data

Journal Articles

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Ravi Vij, MD, Betty Y. Chang, PhD, Jesus G. Berdeja, MD, Carol Ann Huff, M.D., Nikoletta Lendvai, MD PhD, Yu-Tzu Tai, PhD, Stella Chang, Davina Moussa, Joseph J. Buggy, PhD, Laurence Elias, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 4039.

https://doi.org/10.1182/blood.V120.21.4039.4039

Published: 2012

Journal Articles

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Blood (2012) 120 (9): 1877–1887.

https://doi.org/10.1182/blood-2011-12-396853

Published: 2012

Includes: Supplemental data

Journal Articles

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

Blood (2011) 118 (21): 883.

https://doi.org/10.1182/blood.V118.21.883.883

Published: 2011

Journal Articles

Egress of CD19 + CD5 + Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Betty Y Chang, PhD, Michelle Francesco, Padmaja Magadala, Min Mei Huang, PhD, Marcel Spaargaren, PhD, Joseph J. Buggy, PhD, Laurence Elias, MD

Blood (2011) 118 (21): 954.

https://doi.org/10.1182/blood.V118.21.954.954

Published: 2011

Journal Articles

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

John F. DiPersio, MD, PhD, Robert H. Collins, Jr., MD, William Blum, MD, Marcel P Devetten, M.D., Patrick Stiff, MD, Laurence Elias, MD, Anita Reddy, Ph.D., Jennifer A. Smith, Ph.D., H. Jean Khoury, MD

Blood (2009) 114 (22): 633.

https://doi.org/10.1182/blood.V114.22.633.633

Published: 2009

Journal Articles

Leukemic T-PLL Cells Exhibit Short and Narrowly Distributed Telomere Lengths and High Telomerase Activities, Associated with Rapid and Dose-Dependent Cell Death Following Telomerase Inhibition by Imetelstat Sodium.

Gabriela M. Baerlocher, MD, Katia Bassett, PhD, Dirk de Beer, Laurence Elias, MD, Ning F Go, MD, Alexander Roeth, MD

Blood (2009) 114 (22): 2647.

https://doi.org/10.1182/blood.V114.22.2647.2647

Published: 2009

Journal Articles

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Asher Alban Chanan-Khan, MD, Nikhil C. Munshi, MD, Mohamad A. Hussein, M.D., Laurence Elias, MD, Fabio Benedetti, M.D., Jennifer Smith, Ph.D., Soo-Peang Khor, Ph.D., Carol A. Huff, MD

Blood (2008) 112 (11): 3688.

https://doi.org/10.1182/blood.V112.11.3688.3688

Published: 2008

Journal Articles

GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients.

Robert J. Tressler, PhD, Allison C. Chin, Ph.D., Eric J. Feldman, M.D., Kanti R. Rai, M.D., Doug Kornbrust, Ph.D., Calvin B. Harley, Ph.D., Melissa A. Kelly Behrs, Laurence Elias, MD

Blood (2006) 108 (11): 2595.

https://doi.org/10.1182/blood.V108.11.2595.2595

Published: 2006

Journal Articles

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.

Nieves Diaz, MD, Eugeny A. Osmanov, MD, Yulia A. Alexeeva, MD, Mikhail Yu Byakhov, MD, Oleg N. Lipatov, MD, Sergey K. Kravchenko, MD, Ilya S. Zuzgin, MD, Felix T. Garzon, MD, Laurence Elias, MD, Philippe Solal-Celigny, MD.

Blood (2005) 106 (11): 4783.

https://doi.org/10.1182/blood.V106.11.4783.4783

Published: 2005

NARROW

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

Egress of CD19 + CD5 + Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

Leukemic T-PLL Cells Exhibit Short and Narrowly Distributed Telomere Lengths and High Telomerase Activities, Associated with Rapid and Dose-Dependent Cell Death Following Telomerase Inhibition by Imetelstat Sodium.

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients.

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only